Advertisement

Advertisement

PHAT Stock Latest News

Analyst Reaffirms Buy on Phathom as Voquezna Momentum Builds; $28 Price Target Maintained

RatingsAnalyst Reaffirms Buy on Phathom as Voquezna Momentum Builds; $28 Price Target Maintained

Needham pharmaceuticals analysts hold analyst/industry conference call

PremiumThe Fly

Needham pharmaceuticals analysts hold analyst/industry conference call

7d ago

Phathom Shareholders Reaffirm Board, Pay and Auditor

PremiumCompany Announcements

Phathom Shareholders Reaffirm Board, Pay and Auditor

12d ago

Analyst Reiterates Buy on Phathom as Voquezna Strategy Advances; $28 Price Target Maintained

PremiumRatings

Analyst Reiterates Buy on Phathom as Voquezna Strategy Advances; $28 Price Target Maintained

15d ago

Phathom Pharmaceuticals Signals Strong Growth on Earnings Call

PremiumCompany Announcements

Phathom Pharmaceuticals Signals Strong Growth on Earnings Call

1M ago

Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)

PremiumThe FlyPhathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)

1M ago

Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M

The Fly

Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M

1M ago

Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

The Fly

Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

2M ago

Phathom Pharmaceuticals management to meet with Cantor

PremiumThe Fly

Phathom Pharmaceuticals management to meet with Cantor

2M ago

Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up

PremiumCompany Announcements

Phathom Pharmaceuticals Charts Profitable Path After Ramp-Up

3M ago

Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim

PremiumThe Fly

Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim

3M ago

Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating

PremiumRatings

Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating

3M ago

Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs

PremiumThe FlyPhathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs

3M ago

Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)

The Fly

Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)

3M ago

Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M

The Fly

Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M

3M ago

Phathom Pharmaceuticals Announces $130 Million Public Offering

PremiumCompany Announcements

Phathom Pharmaceuticals Announces $130 Million Public Offering

5M ago

Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00

PremiumThe Fly

Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00

5M ago

Closing Bell Movers: Defense stocks surge on Trump military budget comments

PremiumThe Fly

Closing Bell Movers: Defense stocks surge on Trump military budget comments

5M ago

Phathom raises FY25 revenue view to $174.5M-$175.5M from $170M-$175M

PremiumThe Fly

Phathom raises FY25 revenue view to $174.5M-$175.5M from $170M-$175M

5M ago

Phathom Pharmaceuticals announces common stock offering, no amount given

PremiumThe FlyPhathom Pharmaceuticals announces common stock offering, no amount given

5M ago

Phathom Pharmaceuticals files automatic mixed securities shelf

The Fly

Phathom Pharmaceuticals files automatic mixed securities shelf

5M ago

Phathom Pharmaceuticals sees Q4 revenue $57M-$58M, consensus $56.16M

The Fly

Phathom Pharmaceuticals sees Q4 revenue $57M-$58M, consensus $56.16M

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >